Meta-analysis of Association Studies of CYP1A1 Genetic Polymorphisms with Digestive Tract Cancers Susceptibility in Chinese

  • Liu, Chang (Department of Gastroenterology, The First People's Hospital of Chongqing New North Zone) ;
  • Jiang, Zheng (Department of Gastroenterology, University of The First Affiliated Hospital of Chongqing Medical) ;
  • Deng, Qian-xi (Department of Gastroenterology, University of The First Affiliated Hospital of Chongqing Medical) ;
  • Zhao, Ya-nan (Department of Gastroenterology, University of The First Affiliated Hospital of Chongqing Medical)
  • Published : 2014.06.15


Background: A great number of studies have shown that cytochrome P450 1A1 (CYP1A1) genetic polymorphisms, CYP1A1 Msp I and CYP1A1 Ile/Val, might be risk factors for digestive tract cancers, including esophageal cancer (EC), gastric cancer (GC), hepatic carcinoma (HC), as well as colorectal cancer (CC), but the results are controversial. In this study, a meta-analysis of this literature aimed to clarify associations of CYP1A1 genetic polymorphisms with digestive tract cancers susceptibility in Chinese populations. Materials and Methods: Eligible case-control studies published until December 2013 were retrieved by systematic literature searches from PubMed, Embase, CBM, CNKI and other Chinese databases by two investigators independently. The associated literature was acquired through deliberate search and selection based on established inclusion criteria. Fixed-effects or random-effects models were used to estimate odds ratios (ORs and 95%CIs). The meta-analysis was conducted using Review Manager 5.2 and Stata 12.0 softwares with stability evaluated by both stratified and sensitivity analyses. Moreover, sensitivity analysis and publication bias diagnostics confirmed the reliability and stability. Results: Eighteen case-control studies with 1,747 cases and 2,923 controls were selected for CYP1A1 MspI polymorphisms, and twenty case-control studies with 3, 790 cases and 4, 907 controls for the CYP1A1 Ile/Val polymorphisms. Correlation associations between CYP1A1 Ile/Val polymorphisms and digestive tract cancers susceptibility were observed in four genetic models in the meta-analysis (GG vs AA:OR= 2.03, 95%CI =1.52- 2.72; AG vs AA: OR=1.26, 95%CI =1.07-1.48; [GG+AG vs AA] :OR =1.42, 95%CI=1.20-1.68, [GG vs AA+AG]:OR=1.80, 95%CI =1.40-2.31). There was no association between CYP1A1 Msp I polymorphisms and digestive tract cancers risk. Subgroup analysis for tumor type showed a significant association of CYP1A1 Ile/Val genetic polymorphisms with EC in China. However, available data collected by the study failed to reveal remarkable associations of GC or HC with CYP1A1 Ile/Val genetic polymorphisms and EC, GC or CC with CYP1A1 MspI genetic polymorphisms. Conclusions: Our results indicated that CYP1A1 Ile/Val genetic polymorphisms, but not CYP1A1 Msp I polymorphisms, are associated with an increased digestive tract cancers risk in Chinese populations. Additional well-designed studies, with larger sample size, focusing on different ethnicities and cancer types are now warranted to validate this finding.


  1. Chen K, Jin MJ, Fan CH, et al (2005). A case-control study on the association between genetic polymorphism of metaoolic enzymes and the risk of colorectal cancer. Zhonghua Liu Xing Bing Xue Za Zhi, 26, 659-64.
  2. Crewe HK, Notley LM, Wunsch RM, et al (2002). Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes:formation of the 4-hydroxy, 4' -hydroxyl and N-desmethyl metabolites and isomerization of trans 4-hydroxytamoxifen. Drug Metab Dispos, 30, 869-74.
  3. Fan CH, Jin MJ, Zhang Y, et al (2006). Association between genetic polymorphisms of metabolic enzymes and susceptibility of colorectal cancer. Zhonghua Yu Fang Yi Xue Za Zhi, 40, 13-7.
  4. Deng J, Guo R, Yue HW, et al (2008). A case- control study of the polymorphisms of phase i and phase ii metabolic genes and esophageal carcinoma susceptibility. Shiyong Xin Nao Fei Xue Guan Bing Za Zhi, 16, 16-7.
  5. Gao P, Tian Y, Ye XF, et al (2012). Study of CTPIA1, GSTT1, GSTM1 polymorphisms and susceptibility on esophageal carcinoma in Ningxia Hui nationality. Ningxia Yi Xue Za Zhi, 34, 196-9.
  6. Gonzalez CA, Agudo A (2012). Carcinogenesis prevention and early detection of gastric cancer: where we are and where we should go. Int J Cancer, 15,745-53.
  7. Han YB, Feng XX, Li PZ, et al (2005). Case-control study on relationship of CYPIAI and GSTM1 polymorphisms and susceptibility to esophageal squamous carcinoma. Zhongguo Gong Gong Wei Sheng, 21, 3-6.
  8. Han F, Wang X, Wang X, et al (2012). Meta-analysis of the association of CYP1A1 polymorphisms with gastric cancer susceptibility and interaction with tobacco smoking. Mol Bioi Rep, 39, 8335-44.
  9. Huang X, Han ZR, Zhang YH (2012). Association between CYP1A1 gene Msp I polymorphism and esophageal cancer in Guangxi Zhuang nation. Guangxi Yi Ke DaXue Xue Bao, 29, 224-6.
  10. Ji R, Wu Jing, Zhou YN, et al (2010). Relationship between CYP1A1, GSTM1 and GSTT1 genetic polymorphisms and Susceptibility of esophageal cancer in Gansu province. Lanzhou Da Xue Xue Bao, 36, 29-34.
  11. Jun L, Ming YE, Gang W, et al (2013). Nimotuzumab combined with radiotherapy for esophageal cancer:preliminary study of a Phase II clinical trial. Onco Targets Ther, 6, 1589-96.
  12. Li H, Chen XL, Li HQ (2005). Polymorphism of CYPIA1 and GSTMl genes associated with susceptibility of gastric cancer in Shandong Province of China. World J Gastroenterol, 11, 5757-62.
  13. Li R, Shugart YY, Zhou W, et al (2009). Common genetic variations of the cytochrome P450 1A1 gene and risk of hepatocellular carcinoma in a Chinese population. Eur J Cancer, 45, 1239-47.
  14. Liu CL, Jiao HY (2007). Advances of cytochrome P4501A1 gene polymorphisms and the susceptibility of tumour. Int J Genet, 30, 52-6.
  15. Lu H, Yang L, Li Feng, et al (2006). Relationship between polymorphisms of Cytochrome P4501A1 gene and Susceptibility to Esophageal cancer in Kazakh. Nnongken Yi Xue, 28, 81-3.
  16. Luo YP, Chen HC, Khan MA, et al (2011). Genetic polymorphisms of metaoolic enzymes-CYP1A1, CYP2D6, GSTM1, and GSTT1, and gastric carcinoma susceptibility. Tumor Biol, 32,215-22.
  17. Ma JX, Zhang KL, Liu X (2006). Concurrent expression of aryl hydrocarbon receptor and CYP1A1 but not CYP1A1 MspI polymorphism is correlated with gastric cancers raised in Dalian. Cancer Letters, 240, 253-60.
  18. Nan HM, Song YJ, Yun HY, et al (2005). Effects of dietary intake and genetic factors on hypennethylation of the hMLH1 gene promoter in gastric cancer. World J Gastroenterol, 11, 3834-41.
  19. Nimura Y, Yokoyama S, Fujimori M, Aoki T, et al (1997). Genotyping of the CYP1A1 and GSTM1 genes in esophageal carcinoma patients with special reference to smoking. Cancer, 80, 852-7.<852::AID-CNCR4>3.0.CO;2-N
  20. Saeed HM, Alanazi MS, Nounou HA, et al (2013). Cytochrome P450 1A1, 2E1 and GSTM1 gene polymorphisms and susceptibility to colorectal cancer in the Saudi population. Asian Pac J Cancer Prev, 14, 3761-8.
  21. Shao G, Su Y, Huang G, et al (2000). Relationship bettween CYP1A1, GSTM1 genetic polymorphisms and susceptibility to esophageal squamous cell carcinoma. Zhonghua Liu Xing Ring Xue Za Zili, 21, 420-3.
  22. Shen J, Wang RT, Xing HR, et al (2002). Case-control study of the polymorphisms of phase I and phase II metaoolic genes and stonmch cancer susceptibility. Tumor, 22,9-13.
  23. Shen XH, Fu Y, Yuan Y, et al (2005). Association analysis of cyptochrome P450 1a1gene polymorphism with susceptibility to gastric cancer. Dalian Yi Ke Da Xue Xue Bao, 27, 22-4.
  24. Sivaraman L, Leatham MP, Yee J, et al (1994). CYP1A1 genetic polymorphisms and in situ colorectal cancer. Cancer Res, 54, 3692-95.
  25. Wang LD, Zheng S, LiuB, et al (2003). CYP1A1, GSTs and mEH polymorphisms and susceptibility to esophageal carcinoma: Study of population from a high- incidence area in north China. World J Gastroentero, 9, 1394-7.
  26. Wang D, Su M, Tian D, et al (2012). Associations between CYP1A1 and CYP2E1 polymorphisms and susceptibility to esophageal cancer in Chaoshan and Taihang areas of China. Cancer Epidemiol, 36, 276-82.
  27. Wang AH, Sun CS, Li LS, et al (2004). Genetic susceptibility and environmental factors of esophageal cancer in Xi'an. World J Gastroenterol, 10, 940-4.
  28. Wang XW, Zhong TY, Xiong YH, et al (2012). Lack of association Between the CYP1A1 Ile462Val polymorphism and endometrial cancer risk:a meta-analysis. Asian Pac J Cancer Prev, 13,3717-21.
  29. Wideroff L, Vaughan TL, Farin FM, et al (2007). GST, NAT1, CYP1A1 polymorphisms and risk of esophageal and gastric adenocarcinomas. Cancer Detect Prev, 31, 233-6.
  30. World Health Organization (2014). The World Cancer Report. The World Cancer Report. New York.
  31. Wu XH, Yang XY, Duan W, et al (2007). The relationship between genetic polymorphism of cytochrome p450 and susceptibility to hepatocellular carcinoma. Wujing Yi Xue Yuan Xue Bao, 16, 47-8.
  32. Wu MT, Lee JM, Wu DC, et al (2002). Genetic polymorphisms of cytochrome P4501A1 and oesophageal squamous-cell carcinoma in Taiwan. Br J Cancer, 87, 529-32.
  33. Wu B, Liu K, Huang H, et al (2012). Mspl and Ile462Val polymorphisms in CYP1A1 and overall cancer risk a metaanalysis. Plos One, 8, 85166.
  34. Yang J, Yang RS, Li HQ, et al (2004). Study of a CYP1A1 genotype associated with susceptibility to esophageal cancer. Chin J Clin Oncol Rehabil, 11, 9-11.
  35. Yang CX, Matsuo K, Wang ZM, et al (2005). Phase I/II enzyme gene polymorphisms and esophageal cancer risk A metaanalysis of the literature. World J Gastroenterol, 11, 2531-8.
  36. Yeh CC, Sung FC, Tang R, et al (2007). Association between polymorphisms of biotransformation and DNA-repair genes and risk of colorectal cancer in Taiwan. J Biomedical Science, 14, 183-93.
  37. Yin D, Zhang GQ, Deng YC, et al (2010). CYP1A1, GSTM1 genetic polymorphisms and their combined role in susceptibility of esophageal cancer. Zhong Liu Fang Zhi Yan Jiu, 37, 712-6.
  38. Yin LH, Pu YP, Song YH, et al (2005). Polymorphisms of susceptible genes for esophageal cancer risk in Huaian population in Jiangsu province, Tumor, 25, 357-61.
  39. Yin PH, Lee HC, Chau GY, et al (2004). Polymorphisms of estrogen-metabolizing genes and risk of hepatocellular carcinoma in Taiwan females. Cancer Lett, 30, 195-201.
  40. Yu MW, Chiu YH, Yang SY, et al (1999). Cytochrome P450 1A1 genetic polymorphisms and risk of hepatocellular carcinoma among chronic hepatitis Bcamers. Br J Cancer, 80, 598-603.
  41. Yuan X, Zhou G, Zhai Y, et al (2008). Lack of association between the functional polymorphisms in the estrogenmetabolizing genes and risk for hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev, 17, 3621-7.
  42. Yun YX, Wang YP, Wang P, et al (2013). CYP1A1 genetic polymorphisms and risk for esophageal cancer: a casecontrol study in Central China. Asian Pac J Cancer Prev, 14, 6507-12.
  43. Zhang HY, Sun CS. Li LS, et al (2000). Cytochrome P450IA1 and the genetic susceptibility to esophageal carcinoma. Chinese J Preventive Med, 34, 69-71.
  44. Zhang CX, Guo LK, Guo XF (2011). Correlation between drinking beavior and the polymorphisms of CYP1A1-MspI, aldehyde dehydrogenase-2 genes and esophageal carcinoma. Zhonghua wo Nian Xue Zn Zhi, 31, 1976-9.
  45. Zheng LJ , Pang EG, Yang ZW (2009). Study on the relationship between CYP1A1 gene Ile-Val and MspI polymorphism and susceptibility of colorectal cancer. Shanxi Datong Da Xue Xue Bao, 25, 36-8.
  46. Zhou Q, Zhang ZY, Wang LD (2003). Prevalence of genetic polymorphisms of CYP1A1 and 2E1 in subjects with gastric cardia adenocarcinoma at Linzhou, Henan. Zhengzhou Da Xue Xue Bao, 38, 317-9.
  47. Zhou T, Fan W, Han W, et al (2007). The genetic polymorphism and risk factors that associated with the susceptibility of gastric cancer. Zhenghua Xiao Hua Za Zhi, 27, 145-9.
  48. Zhuo WL, Zhang YS, Wang Y, et al (2009). Association Studies of CYP1A1 and GSTM1 Polymorphisms with Esophageal Cancer Risk: Evidence-based Meta-analyses. Arch Med Res, 40, 169-79.
  49. Zhu WC, Chen Q, Luo CL, et al (2001). Relationship study between gene polymorphism of CYP1A1 , GSTMl and genetic susceptibility of primary hepatocellar carcinoma. Zhong Liu Fang Zhi Za Zhi, 8, 572-4.

Cited by

  1. Clinical Observation and Therapeutic Evaluation of Rh-endostatin Combined with DP Regimen in Treating Patients with Advanced Esophageal Cancer vol.15, pp.16, 2014,
  2. Influence of the CYP1A1 T3801C Polymorphism on Tobacco and Alcohol-Associated Head and Neck Cancer Susceptibility in Northeast India vol.16, pp.16, 2015,
  3. Association of CYP1A1 MspI polymorphism in the esophageal cancer risk: a meta-analysis in the Chinese population vol.20, pp.1, 2015,
  4. gene polymorphisms and digestive tract cancer susceptibility: a meta-analysis vol.20, pp.9, 2016,
  5. Cumulative evidence for association between genetic polymorphisms and esophageal cancer susceptibility: A review with evidence from meta-analysis and genome-wide association studies pp.20457634, 2019,